<p>AWM Investment Company Inc. 在第二季度購買了 Abeona Therapeutics Inc.（NASDAQ:ABEO - 免費報告）的新頭寸，根據該公司在最近向 SEC 提交的 13F 表格。該公司購買了 470,000 股生物製藥公司的股票，價值約為 2,670,000 美元。AWM Investment Company Inc. 在最近一個季度末持有約 0.92% 的 Abeona Therapeutics。</p>
<p>獲取 <strong>Abeona Therapeutics</strong> 的提醒：</p>
<p>其他幾家對沖基金最近也調整了對該公司的持股。Creative Planning 在第二季度將其在 Abeona Therapeutics 的股份增加了 43.0%。Creative Planning 目前擁有 14,310 股生物製藥公司的股票，價值 81,000 美元，此前在上個季度又購買了 4,305 股。Ameritas Investment Partners Inc. 在第二季度購買了 Abeona Therapeutics 的新頭寸，價值約為 25,000 美元。Legal &amp; General Group Plc 在第二季度購買了 Abeona Therapeutics 的新股份，價值約為 27,000 美元。OMERS ADMINISTRATION Corp 在第一季度將其在 Abeona Therapeutics 的股份增加了 11.0%。OMERS ADMINISTRATION Corp 目前擁有 72,200 股生物製藥公司的股票，價值 344,000 美元，此前在該期間又收購了 7,155 股。最後，Riverwater Partners LLC 在第二季度購買了 Abeona Therapeutics 的新頭寸，價值約為 62,000 美元。對沖基金和其他機構投資者持有該公司 80.56% 的股票。</p>
<h2>分析師升級和降級</h2>
<p>ABEO 已成為幾份研究報告的主題。HC Wainwright 在 10 月 13 日的報告中重申了對 Abeona Therapeutics 的 &#34;買入&#34; 評級，並給出了 20.00 美元的目標價。Weiss Ratings 在 10 月 24 日的研究報告中將 Abeona Therapeutics 的評級從 &#34;持有（c-）&#34; 降級為 &#34;賣出（d+）&#34;。Oppenheimer 在 8 月 15 日的報告中將 Abeona Therapeutics 的目標價從 19.00 美元上調至 20.00 美元，並給予該股票 &#34;跑贏大盤&#34; 的評級。最後，Wall Street Zen 在 11 月 15 日的研究報告中將 Abeona Therapeutics 的評級從 &#34;持有&#34; 降級為 &#34;賣出&#34;。四位研究分析師對該股票給予了買入評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Abeona Therapeutics 目前的平均評級為 &#34;適度買入&#34;，共識目標價為 20.00 美元。</p>
<p><strong>查看我們對 ABEO 的最新股票分析</strong></p>
<h2>Abeona Therapeutics 股價下跌 2.9%</h2>
<p>ABEO 股票在週五開盤價為 5.36 美元。該公司的債務與股本比率為 0.06，流動比率為 9.74，速動比率為 9.53。該公司的市值為 2.9046 億美元，市盈率為 4.36，貝塔值為 1.12。Abeona Therapeutics Inc. 的一年低點為 3.93 美元，一年高點為 7.54 美元。該公司的 50 日移動平均價格為 4.98 美元，200 日移動平均價格為 5.81 美元。</p>
<p>Abeona Therapeutics（NASDAQ:ABEO - 獲取免費報告）最近於 11 月 12 日發佈了其財報。這家生物製藥公司報告本季度每股收益為（0.10）美元，超出市場共識預期的（0.27）美元，超出幅度為 0.17 美元。整體來看，股票分析師預測 Abeona Therapeutics Inc. 本年度每股收益將為 -1.16 美元。</p>
<h2>內部買賣</h2>
<p>在相關消息中，董事 Mark Alvino 於 11 月 13 日星期四出售了 15,000 股 Abeona Therapeutics 股票。股票以平均價格 4.74 美元出售，總交易額為 71,100.00 美元。交易後，該董事在公司持有 62,252 股，價值約為 295,074.48 美元。此次交易使其持股減少了 19.42%。該交易已在向證券交易委員會的備案中披露，您可以通過此鏈接訪問。此外，首席執行官 Vishwas Seshadri 於 9 月 30 日星期二出售了 25,000 股公司的股票。該股票以平均價格 5.24 美元出售，總交易額為 131,000.00 美元。交易完成後，首席執行官直接持有 1,190,067 股公司的股票，價值 6,235,951.08 美元。這代表其持股減少了 2.06%。有關此次出售的更多細節可在官方 SEC 披露中找到。內部人士在過去 90 天內出售了價值 410,271 美元的 78,612 股公司股票。公司內部人士持有該公司 6.90% 的股票。</p>
<h2>關於 Abeona Therapeutics</h2>
<p>（免費報告）</p>
<p>Abeona Therapeutics Inc. 是一家臨牀階段的生物製藥公司，專注於開發和提供針對嚴重和危及生命的罕見疾病的基因治療產品。該公司的主要項目包括 EB-101（基因修正的皮膚移植）用於隱性營養不良性表皮鬆解症（RDEB）；ABO-102，是針對 A 型 Sanfilippo 綜合症的 AAV 基因治療；以及 ABO-101，是針對 B 型 Sanfilippo 綜合症的腺病毒相關病毒（AAV）基因治療。</p>
<h2>精選故事</h2>
<ul>
<li>我們更喜歡的五隻股票比 Abeona Therapeutics 更好</li>
<li>股票交易術語 - 每個投資者需要了解的股票術語</li>
<li>Synopsys 看到樂觀轉變，因為 Ansys 整合推動增長</li>
<li>投資於高市盈率成長股</li>
<li>你能給自己最好的節日禮物是什麼？Costco 股票</li>
<li>最佳股息貴族名單：通過貴族指數積累財富</li>
<li>為什麼 Zscaler 股票在 30% 的拋售後可能準備反彈</li>
</ul>
<p><strong>想看看其他對沖基金持有 ABEO 的情況嗎？</strong> 訪問 HoldingsChannel.com 獲取 Abeona Therapeutics Inc.（NASDAQ:ABEO - 免費報告）的最新 13F 備案和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJFTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJFTw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Abeona Therapeutics 嗎？</h2>
<p>在考慮 Abeona Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Abeona Therapeutics 並不在名單上。</p>
<p>雖然 Abeona Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Abeona治療

<p>AWM Investment Company Inc. 收購了 470,000 股 Abeona Therapeutics Inc. 的股份，價值 2,670,000 美元，持有該公司 0.92% 的股份。分析師的評級不一，普遍目標價為 20.00 美元。Abeona 的股票開盤價為 5.36 美元，市值為 2.9046 億美元。內部人士最近出售了價值 410,271 美元的股份</p>

<p>AWM Investment Company Inc. bought a new position in Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 470,000 shares of the biopharmaceutical company's stock, valued at approximately $2,670,000. AWM Investment Company Inc. owned approximately 0.92% of Abeona Therapeutics at the end of the most recent quarter.</p>
<div class="lb-trans"><p>AWM Investment Company Inc. 在第二季度購買了 Abeona Therapeutics Inc.（NASDAQ:ABEO - 免費報告）的新頭寸，根據該公司在最近向 SEC 提交的 13F 表格。該公司購買了 470,000 股生物製藥公司的股票，價值約為 2,670,000 美元。AWM Investment Company Inc. 在最近一個季度末持有約 0.92% 的 Abeona Therapeutics。</p>
</div><p>Get <strong>Abeona Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Abeona Therapeutics</strong> 的提醒：</p>
</div><p>Several other hedge funds have also recently modified their holdings of the business. Creative Planning boosted its position in shares of Abeona Therapeutics by 43.0% during the second quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company's stock valued at $81,000 after buying an additional 4,305 shares during the last quarter. Ameritas Investment Partners Inc. bought a new position in Abeona Therapeutics during the 2nd quarter valued at about $25,000. Legal &amp; General Group Plc purchased a new stake in shares of Abeona Therapeutics during the 2nd quarter valued at about $27,000. OMERS ADMINISTRATION Corp grew its stake in shares of Abeona Therapeutics by 11.0% in the first quarter. OMERS ADMINISTRATION Corp now owns 72,200 shares of the biopharmaceutical company's stock worth $344,000 after acquiring an additional 7,155 shares during the period. Finally, Riverwater Partners LLC purchased a new position in shares of Abeona Therapeutics during the second quarter valued at approximately $62,000. Hedge funds and other institutional investors own 80.56% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家對沖基金最近也調整了對該公司的持股。Creative Planning 在第二季度將其在 Abeona Therapeutics 的股份增加了 43.0%。Creative Planning 目前擁有 14,310 股生物製藥公司的股票，價值 81,000 美元，此前在上個季度又購買了 4,305 股。Ameritas Investment Partners Inc. 在第二季度購買了 Abeona Therapeutics 的新頭寸，價值約為 25,000 美元。Legal &amp; General Group Plc 在第二季度購買了 Abeona Therapeutics 的新股份，價值約為 27,000 美元。OMERS ADMINISTRATION Corp 在第一季度將其在 Abeona Therapeutics 的股份增加了 11.0%。OMERS ADMINISTRATION Corp 目前擁有 72,200 股生物製藥公司的股票，價值 344,000 美元，此前在該期間又收購了 7,155 股。最後，Riverwater Partners LLC 在第二季度購買了 Abeona Therapeutics 的新頭寸，價值約為 62,000 美元。對沖基金和其他機構投資者持有該公司 80.56% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級和降級</h2>
</div><p>ABEO has been the topic of several research reports. HC Wainwright restated a &#34;buy&#34; rating and issued a $20.00 target price on shares of Abeona Therapeutics in a report on Monday, October 13th. Weiss Ratings downgraded Abeona Therapeutics from a &#34;hold (c-)&#34; rating to a &#34;sell (d+)&#34; rating in a research note on Friday, October 24th. Oppenheimer lifted their price objective on Abeona Therapeutics from $19.00 to $20.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, August 15th. Finally, Wall Street Zen cut Abeona Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 15th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Abeona Therapeutics presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $20.00.</p>
<div class="lb-trans"><p>ABEO 已成為幾份研究報告的主題。HC Wainwright 在 10 月 13 日的報告中重申了對 Abeona Therapeutics 的 &#34;買入&#34; 評級，並給出了 20.00 美元的目標價。Weiss Ratings 在 10 月 24 日的研究報告中將 Abeona Therapeutics 的評級從 &#34;持有（c-）&#34; 降級為 &#34;賣出（d+）&#34;。Oppenheimer 在 8 月 15 日的報告中將 Abeona Therapeutics 的目標價從 19.00 美元上調至 20.00 美元，並給予該股票 &#34;跑贏大盤&#34; 的評級。最後，Wall Street Zen 在 11 月 15 日的研究報告中將 Abeona Therapeutics 的評級從 &#34;持有&#34; 降級為 &#34;賣出&#34;。四位研究分析師對該股票給予了買入評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Abeona Therapeutics 目前的平均評級為 &#34;適度買入&#34;，共識目標價為 20.00 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on ABEO</strong></p>
<div class="lb-trans"><p><strong>查看我們對 ABEO 的最新股票分析</strong></p>
</div><h2>Abeona Therapeutics Trading Down 2.9%</h2>
<div class="lb-trans"><h2>Abeona Therapeutics 股價下跌 2.9%</h2>
</div><p>Shares of ABEO stock opened at $5.36 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 9.74 and a quick ratio of 9.53. The company has a market cap of $290.46 million, a price-to-earnings ratio of 4.36 and a beta of 1.12. Abeona Therapeutics Inc. has a 1 year low of $3.93 and a 1 year high of $7.54. The firm has a fifty day moving average price of $4.98 and a 200-day moving average price of $5.81.</p>
<div class="lb-trans"><p>ABEO 股票在週五開盤價為 5.36 美元。該公司的債務與股本比率為 0.06，流動比率為 9.74，速動比率為 9.53。該公司的市值為 2.9046 億美元，市盈率為 4.36，貝塔值為 1.12。Abeona Therapeutics Inc. 的一年低點為 3.93 美元，一年高點為 7.54 美元。該公司的 50 日移動平均價格為 4.98 美元，200 日移動平均價格為 5.81 美元。</p>
</div><p>Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17. As a group, equities analysts predict that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current year.</p>
<div class="lb-trans"><p>Abeona Therapeutics（NASDAQ:ABEO - 獲取免費報告）最近於 11 月 12 日發佈了其財報。這家生物製藥公司報告本季度每股收益為（0.10）美元，超出市場共識預期的（0.27）美元，超出幅度為 0.17 美元。整體來看，股票分析師預測 Abeona Therapeutics Inc. 本年度每股收益將為 -1.16 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In related news, Director Mark Alvino sold 15,000 shares of Abeona Therapeutics stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $4.74, for a total transaction of $71,100.00. Following the transaction, the director owned 62,252 shares in the company, valued at approximately $295,074.48. The trade was a 19.42% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, CEO Vishwas Seshadri sold 25,000 shares of the company's stock in a transaction on Tuesday, September 30th. The stock was sold at an average price of $5.24, for a total transaction of $131,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,190,067 shares of the company's stock, valued at $6,235,951.08. This represents a 2.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 78,612 shares of company stock valued at $410,271 in the last 90 days. Corporate insiders own 6.90% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，董事 Mark Alvino 於 11 月 13 日星期四出售了 15,000 股 Abeona Therapeutics 股票。股票以平均價格 4.74 美元出售，總交易額為 71,100.00 美元。交易後，該董事在公司持有 62,252 股，價值約為 295,074.48 美元。此次交易使其持股減少了 19.42%。該交易已在向證券交易委員會的備案中披露，您可以通過此鏈接訪問。此外，首席執行官 Vishwas Seshadri 於 9 月 30 日星期二出售了 25,000 股公司的股票。該股票以平均價格 5.24 美元出售，總交易額為 131,000.00 美元。交易完成後，首席執行官直接持有 1,190,067 股公司的股票，價值 6,235,951.08 美元。這代表其持股減少了 2.06%。有關此次出售的更多細節可在官方 SEC 披露中找到。內部人士在過去 90 天內出售了價值 410,271 美元的 78,612 股公司股票。公司內部人士持有該公司 6.90% 的股票。</p>
</div><h2>About Abeona Therapeutics</h2>
<div class="lb-trans"><h2>關於 Abeona Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.</p>
<div class="lb-trans"><p>Abeona Therapeutics Inc. 是一家臨牀階段的生物製藥公司，專注於開發和提供針對嚴重和危及生命的罕見疾病的基因治療產品。該公司的主要項目包括 EB-101（基因修正的皮膚移植）用於隱性營養不良性表皮鬆解症（RDEB）；ABO-102，是針對 A 型 Sanfilippo 綜合症的 AAV 基因治療；以及 ABO-101，是針對 B 型 Sanfilippo 綜合症的腺病毒相關病毒（AAV）基因治療。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Abeona Therapeutics</li>
<li>Stock Trading Terms - Stock Terms Every Investor Needs to Know</li>
<li>Synopsys Sees Bullish Shift as Ansys Integration Drives Growth</li>
<li>Investing in the High PE Growth Stocks</li>
<li>The Best Holiday Present You Can Give Yourself? Costco Stock</li>
<li>Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index</li>
<li>Why Zscaler Stock Could Be Ready to Bounce After a 30% Selloff</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更喜歡的五隻股票比 Abeona Therapeutics 更好</li>
<li>股票交易術語 - 每個投資者需要了解的股票術語</li>
<li>Synopsys 看到樂觀轉變，因為 Ansys 整合推動增長</li>
<li>投資於高市盈率成長股</li>
<li>你能給自己最好的節日禮物是什麼？Costco 股票</li>
<li>最佳股息貴族名單：通過貴族指數積累財富</li>
<li>為什麼 Zscaler 股票在 30% 的拋售後可能準備反彈</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABEO?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有 ABEO 的情況嗎？</strong> 訪問 HoldingsChannel.com 獲取 Abeona Therapeutics Inc.（NASDAQ:ABEO - 免費報告）的最新 13F 備案和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJFTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ABEO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Abeona Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Abeona Therapeutics 嗎？</h2>
</div><p>Before you consider Abeona Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Abeona Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 Abeona Therapeutics 並不在名單上。</p>
</div><p>While Abeona Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Abeona Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

AWM 投資公司收購 Abeona 治療公司新股份 $ABEO